Brown Rudnick appoints partner
September 27, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Brown rudnick
Sophie McGrath has joined law firm Brown Rudnick as a partner and is to focus on life sciences at the …
Bayer slammed for ‘nightcaps’
September 26, 2013Medical Communications, Sales and Marketing ABPI, Bayer, PMCPA
Bayer has come under fire from the PMCPA for providing late-night drinks to delegates at a conference in Amsterdam, exceeding …
Amgen to open Chinese R&D centre
September 26, 2013Research and Development, Sales and Marketing Amgen, China, R&D, Zhejiang
Amgen has signalled its intention to expand in China by announcing the opening of an R&D centre which will focus …
Merck Serono won’t give up on cancer vaccine
September 26, 2013Sales and Marketing Merck, Merck Serono, Stimuvax
Merck Serono’s once failed lung cancer vaccine treatment Stimuvax has been given a second chance as the German firm begins …
Circassia appoints new chairman from Biogen Idec
September 26, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen IDEC, Circassia, granata
Speciality biopharma firm Circassia has appointed Dr Francesco Granata as its non-executive chairman. Granata is executive in Residence at Warburg …
Roche’s new Herceptin jab approved by NHS
September 25, 2013Sales and Marketing Herceptin, Kadcyla, Roche, breast cancer
MSD’s sugammadex knocked back by FDA – again
September 25, 2013Research and Development, Sales and Marketing FDA, MSD, Merck, Sugammedex
NICE: final ‘no’ for Xalkori
September 25, 2013Sales and Marketing NICE, NSCLC, Pfizer, Xalkori
Pfizer’s worst fears have been confirmed today by NICE, which has rejected its new lung cancer drug Xalkori because of …
Zaicom appoints chief operating officer
September 25, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Zaicom, cossins
Zaicom International which focusses on comms, market research and regulatory solutions in healthcare has appointed Stuart Cossins as its chief …
FDA: we won’t regulate most apps
September 24, 2013Medical Communications, Sales and Marketing FDA, apps, iphone
Pandemrix narcolepsy U-turn by government
September 24, 2013Sales and Marketing GSK, Pandemrix, flu vaccine, government
The government has acknowledged that a GSK flu vaccine administered during the swine flu breakout could have caused children to …
Pharma makes progress on continuous processing
September 24, 2013Manufacturing and Production continuos processing, pharma
The drug industry has lagged behind other sectors in adopting more efficient manufacturing, but there are signs that one key …
Pfizer begins using ‘digital’ reps
September 24, 2013Medical Communications, Sales and Marketing Pfizer, online, pfizerline, reps
Pfizer has begun using digital drug representatives to market medicines, leaving the decision as to whether they want to see …
PAN promotes Sarah Verhoeff to Board director
September 24, 2013Medical Communications, Research and Development, Sales and Marketing Pan, verhoeff
Sarah Verhoeff who joined PAN in January has been promoted to director and joins the agency’s Board. Previously business director …
Boehringer and Ventana link up
September 24, 2013Research and Development, Sales and Marketing Boehringer, Ventana, oncology
Boehringer Ingelheim has signed a deal with Roche subsidiary Ventana Medical Systems to develop companion diagnostic tests for Boehringer’s oncology …
Novartis backs new anti-malaria campaign
September 23, 2013Medical Communications, Sales and Marketing Novartis, donation, malaria
CHMP recommends cancer ‘smart bomb’
September 23, 2013Research and Development, Sales and Marketing CHMP, Cancer, EMA, Kadcyla, Roche
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
